Guilford Gliadel to be priced at $6,000 to $8,000 per treatment, CEO tells analysts.
Executive Summary
GUILFORD GLIADEL WILL COST $6,000 TO $8,000 PER TREATMENT, which consists of eight polymer wafers containing the chemotherapeutic agent carmustine, Guilford CEO Craig Smith, MD, told analysts at the Alex. Brown conference in Baltimore. A Treatment IND for Gliadel is approaching 75 patients enrolled, Smith said. The company filed an NDA for Gliadel for the treatment of malignant glioma as an adjunct to brain surgery in February, and the product will be reviewed by the FDA Oncologic Drugs Advisory Committee on June 14 ("The Pink Sheet" May 13, In Brief).